| Prev Close | 308.04 |
| Day Low/High | 303.70 / 309.21 |
| 52 Wk Low/High | 291.10 / 442.00 |
| Avg Volume | 792.90K |
Regeneron Pharmaceuticals Inc. (REGN)
304.94
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 107.73M |
| Market Cap | 33.77B |
| EPS | 22.60 |
| P/E Ratio | 14.59 |
| Div & Yield | N.A. (N.A) |
Anatomy of a Rally: Simpler Than You Think
Understanding why stocks act the way they do.
Grasping at Growth: The Hunt Is On
Once again, buyers are going for the gusto.
5 Biotech Stocks With Bullish Charts That Will Push the Sector Higher
The common thread in these 5 names is the bullish divergence between the lower lows in price and the higher low in the momentum study.
Regeneron Has More Upside to Go
The stock shows bullish momentum and could climb 5%.
We're Feeling Better About Growth Stocks
Amazon is among the indicators.
Eli Lilly's Stock Is Worth a Chance Below $80
The company's stock will likely be among the first to turn.
Plenty of Good News -- If You Look
Not all growth is hated today.
Drug Stocks' Earnings Power Won't Go Away
Before you sell them, ask yourself at what multiple you sell.
Jim Cramer: Could Glencore Be the Next Long Term Capital?
Jim Cramer answered viewers’ Twitter (TWTR) questions from the floor of the Stock Exchange and said he's not assuaged by Glencore's (GLCNF) comments that it is ‘operationally and financially robust.'
These Biotech Trades are a Great Rx
Hillary Clinton has created some good short-term opportunities.
It May Be Early, but Check Out the Moves in These Stocks
High-growth, REIT and consumer names clearly want to go higher.
Regeneron Chart Looks Rejuvenated
Shares appear ready to return to previous highs.
Not the Kind of Waves You Want to Make
On days like this, bizarre action is the norm.
It's OK, Market: Some (But Not All) Is Forgiven
But this might be a good time to sell.
This Volatility in the Indices Is Just Plain Phony
It's just machine to machine, but we are haunted by 2008.
Build a Core Position in Biotech Intrexon at These Lower Prices
Following a 40% decline, now looks good for scaling into the stock.
Even Stocks With Bullish Outlooks Are Not Safe in the Market Carnage
Which means interest rate hikes are being built into prices.
Regeneron Shows a High Volume Bottom
Regeneron shows its relative strength in the market selloff.
How China's Troubles Affect Biotech and Pharma Stocks: Part 1
At first glance there is little connection, but you need to look deeper.
Odds Are Regeneron Rally Can Continue
My maximum risk can be defined below the July 27 low.
Finally, Respite From the Volatility
Still, momentum is cooling and valuation is an issue in more cases.
Stocks With Significant High Activity: the First Four Groups
There are some good buying ideas among these stocks.
The Market Reacts Rationally for Once
High-growth names, big commodity-takers, consumer plays shine today.
You Can Run, But You Can't Hide Today
There's no such thing as a 'safe harbor' right now on Wall Street.
Jim Cramer Won't Turn on Apple, Doesn't Like Twitter Until $19.20
Jim Cramer answers viewers' Twitter questions from the floor of the New York Stock Exchange.
Futures Tick Higher; Obama Pushes Emissions Reductions
Coal and renewables could both react as political and legal battles ensue.
Cramer: Biogen's Horseman May Have Fallen Off, I Like Others More
TheStreet's Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
When Leader Goes Down, Whole Sector Feels It
Biogen's weak numbers leave biotechs ailing.
Are Any New FANGs Baring Their Teeth?
The fearsome foursome have been reborn.
